30 results about "Disorder lipid metabolism" patented technology

The invention discloses application of 4-chloro-2-(5-phenyl-1-(pyridine-2-yl)-4, 5-dihydro-1H-pyrazol-3-yl) phenol in preparation of medicaments for inhibiting fatty liver and stabilizing atherosclerotic plaques. The dose of 4-chloro-2-(5-phenyl-1-(pyridine-2-yl)-4,5-dihydro-1H-pyrazol-3-yl) phenol for effectively inhibiting the fatty liver and stabilizing the atherosclerotic plaques is 5-20mu g / kg / day. 4-chloro-2-(5-phenyl-1-(pyridine-2-yl)-4, 5-dihydro-1H-pyrazol-3-yl) phenol provided by the invention lays a foundation for development of the medicaments for treating the fatty liver and arteriosclerosis and can be used as a powerful tool for researching a molecular mechanism of abnormal lipid metabolism and unstable atherosclerotic plaques.

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention discloses a PPAR (peroxisome proliferator-activated receptor) alpha-gamma dual agonist and an application thereof. The PPAR alpha-gamma dual agonist contains an effective quantity of a derivative represented by the formula I or the formula II in the description and a pharmaceutically acceptable salt of the derivative, wherein definition of each substituent group is as claimed in theclaims and the description. Experiments prove that the compound represented as the formula I or the formula II can remarkably improve PPAR alpha-gamma transcriptional activity and mRNA level of related target genes, has PPAR alpha-gamma dual agonist activity and can be taken as an effective component of the PPAR alpha-gamma dual agonist. The PPAR alpha-gamma dual agonist can be applied to preparation of drugs and healthy food for preventing or / and treating metabolic syndromes, particularly can be applied to preparation of drugs and healthy food for preventing or / and treating abnormal glucose metabolism or / and abnormal lipids metabolism diseases, and has broad application prospect.

The invention discloses a Docynia delavayi polyphenol extract which has polyphenol content of 91.24 to 91.34% (w / w). The invention also provides a preparation method for the extract. With extraction conditions provided in the invention, polyphenol substances can be maximally extracted from Docynia delavayi, and an extraction rate is as high as 18.54%. High-purity polyphenol and phlorizin can be obtained by further purifying a crude extract with the purifying method provided by the invention. Pharmacological experiments show that the Docynia delavayi polyphenol extract can substantially reduce the levels of cholesterol TC, triglyceride TG, high-density lipoprotein HDL-C and low-density lipoprotein LDL-C in the serum of mice; thus, the Docynia delavayi polyphenol extract can effectively prevent and treat diseases related to abnormal lipids metabolism, such as obesity resulting from abnormal blood fat content, hyperlipidemia, atherosclerosis and coronary heart diseases.

The invention discloses a traditional Chinese medicine composition for treating level-1 and level-2 hypertension and a preparation method of the composition. The traditional Chinese medicine composition for treating level-1 and level-2 hypertension is characterized by comprising the following raw medical materials: ligusticum wallichii, rhizoma alismatis, semen raphani, seaweed and leech; and the traditional Chinese medicine composition is prepared through the steps of decocting, carrying out alcohol precipitation and the like for the raw medicinal liquid with the preparation amount. The traditional Chinese medicine composition has remarkable therapeutic effects on the level-1 and level-2 hypertension, not only reduces blood pressure, but also improves blood grease level of a patient and the hemorheology, increases a heart function, and is good for correcting disordered lipid metabolism of the patient. The preparation method is simple and good for production, and has no side effect.

The invention discloses a compound earthworm protein preparation for the assistant adjustment of blood fat. The compound earthworm protein preparation is composed of earthworm proteins, chitosan and selectable assistants. The preparation has a reasonable formula and substantial efficacies. Blood fat reduction assisting function examinations of the preparation, comprising animal tests of rats having disordered lipid metabolisms and human administration tests, are carried out by Nanjing Public Health Preventive Medicine Institute according to the Standard of Health Food Test and Assess (2003) published by the ministry of health, and results prove that the preparation has a blood fat reduction assisting effect. The preparation makes an attempt and a contribution to the application of traditional Chinese medicine earthworm in the healthcare food field.